• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.33% Nasdaq Up1.33%

    ACADIA Pharmaceuticals Inc. (ACAD)

    -NasdaqGS
    32.46 Up 0.08(0.25%) 4:00PM EDT
    |After Hours : 32.43 Down 0.03 (0.09%) 7:28PM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    ACADIA Pharmaceuticals Inc.
    3611 Valley Centre Drive
    Suite 300
    San Diego, CA 92130
    United States - Map
    Phone: 858-558-2871
    Fax: 858-558-2872
    Website: http://www.acadia-pharm.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:320

    Business Summary 

    ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer’s disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on ACADIA Pharmaceuticals Inc.

    Corporate Governance 
    ACADIA Pharmaceuticals Inc.’s ISS Governance QuickScore as of Jun 1, 2016 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Stephen R. Davis J.D., 55
    Chief Exec. Officer, Pres and Director
    856.00K0.00
    Mr. Glenn F. Baity , 46
    Exec. VP, Gen. Counsel and Sec.
    508.00K0.00
    Mr. Terrence O. Moore , 62
    Chief Commercial Officer and Exec. VP
    532.00K0.00
    Dr. Srdjan Stankovic M.D., MSPH, 59
    Head of R&D and Exec. VP
    1.79M0.00
    Ms. Teri L. Chuppe , 53
    VP of Fin.
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders